LifeMD expands its pharmacy services to include non-sterile compounding for customized medications, enhancing patient care accessibility.
Quiver AI Summary
LifeMD, Inc. has announced the expansion of its affiliated pharmacy to include advanced non-sterile compounding capabilities for customized oral and topical medications. This initiative enhances LifeMD's vertical integration strategy, allowing the company to create tailored therapies that cater to specific patient needs, while streamlining operations and reducing dependence on external providers. Launched in August 2024, the pharmacy can process up to 5,000 prescriptions daily and now offers unique formulations, including allergen-free options and products not widely available. The expansion strengthens LifeMD’s services in various health areas and aims to improve patient care quality and accessibility. The pharmacy operates under FDA regulations and is currently licensed in 13 states, with plans to expand to all 50 states within the next year.
Potential Positives
- Expansion of pharmacy capabilities to include advanced non-sterile compounding for oral and topical medications, enhancing service offerings.
- Ability to formulate customized medications, including allergen-free and combination products, that are not commercially available, catering to specific patient needs.
- Strengthening operational efficiency with reduced reliance on third-party providers, potentially leading to cost savings and improved patient satisfaction.
- Plan to attain pharmacy licenses in all 50 states within the next 12 months, significantly increasing market reach and access to services.
Potential Negatives
- The announcement of expansion into non-sterile compounding could raise concerns about the complexities and regulatory challenges associated with customized medication formulations, potentially impacting operational efficiency.
- While the company expresses confidence in meeting safety and quality standards, any future issues related to regulatory compliance could lead to significant reputational and operational risks.
- LifeMD's commitment to expand its pharmacy services across all 50 states within the next year may strain resources and operational capabilities, leading to potential challenges in execution and service delivery quality.
FAQ
What recent expansion has LifeMD announced for its pharmacy services?
LifeMD has expanded its pharmacy to include non-sterile compounding capabilities for customized oral and topical medications.
How does LifeMD's pharmacy support patient care?
The pharmacy offers tailored therapies, reduces reliance on third-party providers, and improves operational efficiency for patient convenience.
What is the capacity of LifeMD's pharmacy for processing prescriptions?
LifeMD’s commercial pharmacy can process up to 5,000 prescriptions per day since its launch in August 2024.
In how many states is LifeMD’s pharmacy currently licensed?
LifeMD's pharmacy is licensed in 13 states with plans to attain licenses in all 50 states within the next year.
What areas of health does LifeMD's compounding pharmacy focus on?
The compounding pharmacy aligns with LifeMD's services in men's and women's health, dermatology, and other specialized therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LFMD Insider Trading Activity
$LFMD insiders have traded $LFMD stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $LFMD stock by insiders over the last 6 months:
- MARC DAVID BENATHEN (Chief Financial Officer) has made 0 purchases and 2 sales selling 125,000 shares for an estimated $1,682,440.
- JUSTIN SCHREIBER (Chairman and CEO) has made 0 purchases and 6 sales selling 150,000 shares for an estimated $1,473,065.
- STEFAN GALLUPPI (Chief Innovation Officer) sold 85,000 shares for an estimated $1,052,657
- NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760
- ERIC HAROLD YECIES (Chief Legal Officer & GC) sold 15,000 shares for an estimated $183,750
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LFMD Hedge Fund Activity
We have seen 91 institutional investors add shares of $LFMD stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NUVEEN, LLC added 882,362 shares (+310.7%) to their portfolio in Q2 2025, for an estimated $12,017,770
- UBS GROUP AG added 859,444 shares (+1103.4%) to their portfolio in Q2 2025, for an estimated $11,705,627
- MORGAN STANLEY added 847,262 shares (+113.6%) to their portfolio in Q2 2025, for an estimated $11,539,708
- D. E. SHAW & CO., INC. added 643,978 shares (+111.8%) to their portfolio in Q2 2025, for an estimated $8,770,980
- RENAISSANCE TECHNOLOGIES LLC added 600,100 shares (+123.5%) to their portfolio in Q2 2025, for an estimated $8,173,361
- CITADEL ADVISORS LLC removed 485,182 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,608,178
- TWO SIGMA INVESTMENTS, LP added 420,127 shares (+1382.0%) to their portfolio in Q2 2025, for an estimated $5,722,129
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LFMD Analyst Ratings
Wall Street analysts have issued reports on $LFMD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/07/2025
- Lake Street issued a "Buy" rating on 08/06/2025
To track analyst ratings and price targets for $LFMD, check out Quiver Quantitative's $LFMD forecast page.
$LFMD Price Targets
Multiple analysts have issued price targets for $LFMD recently. We have seen 4 analysts offer price targets for $LFMD in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $13.0 on 08/07/2025
- Scott Schoenhaus from Keybanc set a target price of $12.0 on 08/06/2025
- Brooks O'Neil from Lake Street set a target price of $14.0 on 08/06/2025
Full Release
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD’s pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing reliance on third-party providers.
LifeMD’s commercial pharmacy, launched in August 2024 with capacity to process up to 5,000 prescriptions per day, can now formulate customized medications, including allergen-free and combination products not commercially available. These capabilities align with LifeMD’s core service areas in men’s and women’s health, dermatology, and beyond. The addition strengthens the Company’s ability to support specialized therapies while driving operational savings, shortening fulfillment times, and improving patient convenience.
“Every action we take is focused on strengthening LifeMD’s ability to deliver higher-quality, more accessible care to our patients,” said Justin Schreiber, Chairman and CEO of LifeMD. “By expanding our pharmacy with non-sterile compounding, we are not just adding capabilities, we’re building toward a future where every patient’s care is seamless, personalized, and accessible. This advancement complements our core service areas and brings us closer to delivering an unmatched healthcare experience, where convenience, continuity, and innovation come together to provide the kind of care that people want and deserve.”
LifeMD’s compounding pharmacy operates under the U.S. Food and Drug Administration’s 503A designation to directly meet specific patient needs with custom-formulated products. The Company is committed to adhering to strict quality and safety standards set by both federal and state regulations. LifeMD’s pharmacy is currently licensed in 13 states, with expectations to attain licenses in all 50 states within the next 12 months.
About LifeMD, Inc.
LifeMD ® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com .
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
[email protected]
Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
[email protected]